Program
glumetinib
Also written as “Glumetinib”, “Gumarontinib Tablets” and “Glumetinib Tablets”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haihe Biopharma | 51 open or running | phase 2since Aug 7, 2019 | Aug 7, 2017 | none ahead |
| CSPC Pharmaceutical Group | 33 open or running | phase 3since Feb 11, 2025 | Jul 18, 2024 | Dec 25, 2026phase 2 · NCT06525350 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 7, 2017First study: phase 1 study in Advanced Solid TumorNew to Haihe BiopharmaHaihe Biopharma · NCT03466268 · 56 enrolled · China
- Feb 9, 2018Phase 1 study in Advanced Solid TumorHaihe Biopharma · NCT03457532 · 177 enrolled · China
- Aug 7, 2019Phase 2 study in C-Met Exon 14 MutationHaihe Biopharma · NCT04270591 · 183 planned · United States, China, Japan
- Mar 29, 2020Phase 2 study in Negative T790M Mutation and Met AmplificationHaihe Biopharma · NCT04338243 · 70 enrolled · China
- Aug 17, 2022Phase 1 study in Healthy VolunteersHaihe Biopharma · NCT05507294 · 18 enrolled · China
- Jul 18, 2024CSPC Pharmaceutical Group's first study: phase 2 study in RecurrenceNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06525350 · 256 planned
- Feb 11, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT06829459 · 350 planned · China
- Mar 27, 2025Phase 3 study in RecurrenceCSPC Pharmaceutical Group · NCT06908772 · 390 planned
Ahead
- Dec 25, 2026Primary completion: phase 2 study in RecurrenceCSPC Pharmaceutical Group · NCT06525350
- Feb 15, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT06829459
- Dec 31, 2028Primary completion: phase 3 study in RecurrenceCSPC Pharmaceutical Group · NCT06908772
TargetBeta
“An orally bioavailable, small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), ”NCIt, by rule
Other programs on MET
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Crizotinibrule | Pfizer | phase 4 | 31 |
| telisotuzumab adizutecan | AbbVie | phase 3 | 18 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| vebreltinibrule | beijing-pearl-biotechnology-limited-liability-company | phase 3 | 9 |
| vilzemetkib | Sino Biopharmaceutical | phase 3 | 8 |
| dalmelitinib | Hansoh Pharmaceutical Group | phase 3 | 7 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| SHR-1826 | Jiangsu HengRui Medicine | phase 2 | 7 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06908772Recurrence | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Dec 31, 2028 | 390 |
| NCT06829459Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | CSPC Pharmaceutical Group | Feb 15, 2028 | 350 |
| NCT06525350Recurrence | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Dec 25, 2026 | 256 |
| NCT05507294Healthy Volunteers · China | 1 | Completed | Haihe Biopharma | May 21, 2021 | 18 |
| NCT04338243Negative T790M Mutation and Met Amplification · China | 2 | UNKNOWN | Haihe Biopharma | Dec 31, 2020 | 70 |
| NCT04270591C-Met Exon 14 Mutation · United States, China, Japan | 2 | Recruiting | Haihe Biopharma | Oct 25, 2023 | 183 |
| NCT03457532Advanced Solid Tumor · China | 1 | Completed | Haihe Biopharma | Sep 22, 2023 | 177 |
| NCT03466268Advanced Solid Tumor · China | 1 | Completed | Haihe Biopharma | Jan 9, 2023 | 56 |
How it is read
Names in the registry
- “Glumetinib”, 4 entries
- “Gumarontinib Tablets”, 2 entries
- “Glumetinib Tablets”, 1 entry
- “Glumetinib tablets”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.